Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

309
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
309
Adrenergic Agonists: Therapeutic Uses01:30

Adrenergic Agonists: Therapeutic Uses

1.5K
Adrenergic agonists have diverse therapeutic uses across various medical conditions and emergencies.
Emergency and Intensive Care Unit (ICU) applications: Pressor agents increase blood pressure, heart rate, and contractility in shock and organ failure situations. Dopamine can induce vasodilation and stimulate adrenoceptors. Endogenous catecholamines are effective in treating cardiogenic shock. α2-agonists like clonidine can reverse anesthesia-induced hypertension.
Allergies and...
1.5K
Direct-Acting Cholinergic Agonists: Therapeutic Uses01:11

Direct-Acting Cholinergic Agonists: Therapeutic Uses

1.4K
Direct-acting cholinergic agonists have many therapeutic uses in various medical fields. Choline esters, including acetylcholine, have limited clinical utility due to their non-selectivity and short duration of action. Still, acetylcholine and carbachol are applied topically during ophthalmologic surgery to induce miosis. Pilocarpine, a muscarinic and ganglionic stimulator, effectively treats open-angle glaucoma and alleviates xerostomia and dry mouth caused by radiotherapy or Sjögren...
1.4K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

717
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
717
Drug Therapy01:28

Drug Therapy

184
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
184
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

345
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
345

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Principles of resident tissue macrophages revealed by the eye.

Advances in immunology·2026
Same author

Therapeutic Opportunities Targeting the ACE2/Ang-(1-7)/MasR Pathway in Cardiometabolic Disease.

Current hypertension reports·2026
Same author

Association and Multimodal Model of Retinal Mid-Peripheral Capillary Free Zones with Structural and Functional Parameters in Diabetic Patients Without Clinical Retinopathy.

Ophthalmic & physiological optics : the journal of the British College of Ophthalmic Opticians (Optometrists)·2026
Same author

Mondo family proteins in diabetes.

Frontiers in endocrinology·2026
Same author

Resilient Calvarial Bone Marrow Supports Retinal Repair in Type 2 Diabetes.

Advanced science (Weinheim, Baden-Wurttemberg, Germany)·2026
Same author

Indole-3-propionic acid links gut dysfunction to diabetic retinopathy: a biomarker and novel therapeutic approach.

Gut·2025

Related Experiment Video

Updated: Dec 5, 2025

Author Spotlight: Insights and Innovations in Gene Expression Manipulation Techniques for Choroid Plexus Research
04:43

Author Spotlight: Insights and Innovations in Gene Expression Manipulation Techniques for Choroid Plexus Research

Published on: June 16, 2023

1.3K

ACE2 as therapeutic agent.

Qiuhong Li1, Maria B Grant2, Elaine M Richards3

  • 1Department of Ophthalmology, University of Florida College of Medicine, Gainesville, FL, U.S.A.

Clinical Science (London, England : 1979)
|October 16, 2020
PubMed
Summary

Enhancing the angiotensin-converting enzyme 2 (ACE2) and its downstream signaling pathway offers therapeutic potential for cardiovascular homeostasis. This review explores strategies to boost ACE2 activity, addressing challenges and future directions.

Keywords:
ACE2Angiotensin IIAngiotensin-(1-7)Probioticsgene deliveryrenin-angiotensin system

More Related Videos

A Step-By-Step Method to Detect Neutralizing Antibodies Against AAV using a Colorimetric Cell-Based Assay
05:53

A Step-By-Step Method to Detect Neutralizing Antibodies Against AAV using a Colorimetric Cell-Based Assay

Published on: December 7, 2021

5.1K
Subconjunctival Administration of Adeno-associated Virus Vectors in Small Animal Models
06:16

Subconjunctival Administration of Adeno-associated Virus Vectors in Small Animal Models

Published on: March 16, 2022

3.5K

Related Experiment Videos

Last Updated: Dec 5, 2025

Author Spotlight: Insights and Innovations in Gene Expression Manipulation Techniques for Choroid Plexus Research
04:43

Author Spotlight: Insights and Innovations in Gene Expression Manipulation Techniques for Choroid Plexus Research

Published on: June 16, 2023

1.3K
A Step-By-Step Method to Detect Neutralizing Antibodies Against AAV using a Colorimetric Cell-Based Assay
05:53

A Step-By-Step Method to Detect Neutralizing Antibodies Against AAV using a Colorimetric Cell-Based Assay

Published on: December 7, 2021

5.1K
Subconjunctival Administration of Adeno-associated Virus Vectors in Small Animal Models
06:16

Subconjunctival Administration of Adeno-associated Virus Vectors in Small Animal Models

Published on: March 16, 2022

3.5K

Area of Science:

  • Cardiovascular Physiology
  • Enzymology
  • Pharmacology

Background:

  • The renin-angiotensin system (RAS) is crucial for cardiovascular homeostasis, regulating vascular tone and fluid balance.
  • Angiotensin-converting enzyme 2 (ACE2) hydrolyzes Angiotensin-II to Angiotensin-(1-7), which counteracts Angiotensin-II's effects via the Mas receptor.
  • The ACE2/Ang-(1-7)/Mas axis demonstrates beneficial effects in various pathological conditions.

Purpose of the Study:

  • To provide an overview of current strategies for enhancing ACE2 activity as a therapeutic agent.
  • To discuss the limitations and future challenges associated with ACE2-based therapeutics.
  • To explore the implications of ACE2's other functions, including amino acid transport and viral entry, on therapeutic development.

Main Methods:

  • Literature review of experimental models and therapeutic strategies.
  • Analysis of signaling pathways involving ACE2, Angiotensin-(1-7), and the Mas receptor.
  • Discussion of ACE2's diverse biological functions and their therapeutic relevance.

Main Results:

  • Evidence supports the beneficial effects of enhancing the ACE2/Ang-(1-7)/Mas axis in experimental models.
  • ACE2 plays a dual role, with potential therapeutic benefits but also serving as a viral entry receptor.
  • Various strategies exist to enhance ACE2 activity, but challenges remain.

Conclusions:

  • Enhancing the ACE2/Ang-(1-7)/Mas axis is a promising therapeutic strategy for cardiovascular and other diseases.
  • Understanding ACE2's multifaceted roles is critical for developing safe and effective ACE2-based therapies.
  • Future research should focus on overcoming limitations and addressing challenges in translating ACE2 enhancement into clinical practice.